Zixin Pharmaceutical's net profit is further questioned, and Zengyi industrial cannabis, blockchain and other hot spots

Zixin Pharmaceutical was once again questioned because of the mismatch between its net profit and cash flow for the year of 2018. "Investor Network" contacted Zixin Pharmaceutical, the company did not give any reply. According to the 2018 annual report, the operating income was 1.325 billion yuan, down 0.17% year-on-year; the net profit was 174 million yuan, down 53% year-on-year; the net profit attributable to shareholders of the parent company was 160 million yuan, down 56% year-on-year. The income fell slightly but the net profit plummeted, causing many investors to question. The strange data is that the net cash flow generated by Zixin Pharmaceutical's business activities in 2018 was -7.7 billion, a year-on-year decrease of 42%. Why this? What is the difference between the net profit and the net profit? In this regard, the company said that due to the expansion of the company's business scale, the company made a full strategic reserve for the company's sustainable production and operation, the company's procurement expenditure cash flow increased, the net cash flow from operating activities was negative, with the company's three major businesses The sector continued to advance, resulting in a difference between the net cash flow generated by the company's operating activities during the reporting period and the net profit for the year. In addition, there is another piece of data that is particularly eye-catching, and that is inventory. The data shows that the company's inventory in 2018 was as high as 6.126 billion yuan, which is the highest record since its listing. It is worth noting that Zixin Pharmaceutical is keen on hotspots, and it is not once and twice the layout of related businesses and there is no real benefit in the future, from the initial concept of ginseng to the concept of genetic testing in 2013, to the block last year. chain.